BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RGN-259: Phase II started

RegeneRx began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily RGN-259 for 30 days in 72 patients.

RegeneRx Biopharmaceuticals...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >